Felippe Borlot1,2, Bruno Ivo de Almeida1,3, Shari L Combe1, Danielle M Andrade2,4,5, Francis M Filloux1, Kenneth A Myers6,7. 1. Department of Neurology, University of Utah, Salt Lake City, Utah. 2. Division of Neurology, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada. 3. Faculty of Biology, University of Bordeaux, Talence, France. 4. Epilepsy Genetics Program, Krembil Neuroscience Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 5. Division of Neurology, Krembil Neuroscience Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Research Institute of the McGill University Health Centre, Montreal, Québec, Canada. 7. Montreal Children's Hospital, McGill University, Montreal, Québec, Canada.
Abstract
OBJECTIVE: To determine the diagnostic yield of a commercial epilepsy gene panel in adults with chronic epilepsy and accompanying intellectual disability, given that genetic evaluation is often overlooked in this group of patients. METHODS: This is a cross-sectional study analyzing the results of epilepsy gene panels including up to 185 genes in adult epilepsy patients with intellectual disability, according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition. Patients with acquired structural brain abnormalities or known chromosomal abnormalities were excluded. RESULTS: From approximately 600 patients seen from January 2017 to June 2018 at a single academic epilepsy center, 64 probands and two affected relatives (32 males, mean age = 31 years ± 10) were selected and clinically tested. Fourteen probands (14/64 = 22%; four males, mean age = 32 years ± 10) were found to have pathogenic or likely pathogenic variants in the following genes: SCN1A, GABRB3, UBE3A, KANSL1, SLC2A1, KCNQ2, SLC6A1, HNRNPU, STX1B, SCN2A, PURA, and CHD2. Six variants arose de novo, and the inheritance was not determined in eight. Nine probands (64%) had severe or profound intellectual disability, and five (35%) had autistic features. Eight patients (57%) had a diagnostic change from presumptive clinical diagnosis prior to genetic testing. SIGNIFICANCE: We were able to demonstrate that a commercial epilepsy gene panel can be an important resource in clinical practice, identifying the etiology in 22% of adults with epilepsy and intellectual disability. The diagnostic yield is similar to previously reported pediatric cohorts. Larger samples would be required to evaluate the more prevalent genotypes among adult epilepsy patients. Wiley Periodicals, Inc.
OBJECTIVE: To determine the diagnostic yield of a commercial epilepsy gene panel in adults with chronic epilepsy and accompanying intellectual disability, given that genetic evaluation is often overlooked in this group of patients. METHODS: This is a cross-sectional study analyzing the results of epilepsy gene panels including up to 185 genes in adult epilepsypatients with intellectual disability, according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition. Patients with acquired structural brain abnormalities or known chromosomal abnormalities were excluded. RESULTS: From approximately 600 patients seen from January 2017 to June 2018 at a single academic epilepsy center, 64 probands and two affected relatives (32 males, mean age = 31 years ± 10) were selected and clinically tested. Fourteen probands (14/64 = 22%; four males, mean age = 32 years ± 10) were found to have pathogenic or likely pathogenic variants in the following genes: SCN1A, GABRB3, UBE3A, KANSL1, SLC2A1, KCNQ2, SLC6A1, HNRNPU, STX1B, SCN2A, PURA, and CHD2. Six variants arose de novo, and the inheritance was not determined in eight. Nine probands (64%) had severe or profound intellectual disability, and five (35%) had autistic features. Eight patients (57%) had a diagnostic change from presumptive clinical diagnosis prior to genetic testing. SIGNIFICANCE: We were able to demonstrate that a commercial epilepsy gene panel can be an important resource in clinical practice, identifying the etiology in 22% of adults with epilepsy and intellectual disability. The diagnostic yield is similar to previously reported pediatric cohorts. Larger samples would be required to evaluate the more prevalent genotypes among adult epilepsypatients. Wiley Periodicals, Inc.
Authors: Ana Julia da Cunha Leite; Irene Plaza Pinto; Nico Leijsten; Martina Ruiterkamp-Versteeg; Rolph Pfundt; Nicole de Leeuw; Aparecido Divino da Cruz; Lysa Bernardes Minasi Journal: PLoS One Date: 2022-04-07 Impact factor: 3.240
Authors: Giulia Spoto; Giulia Valentini; Maria Concetta Saia; Ambra Butera; Greta Amore; Vincenzo Salpietro; Antonio Gennaro Nicotera; Gabriella Di Rosa Journal: Front Neurol Date: 2022-03-08 Impact factor: 4.003
Authors: Dianalee McKnight; Sara L Bristow; Rebecca M Truty; Ana Morales; Molly Stetler; M Jody Westbrook; Kristina Robinson; Darlene Riethmaier; Felippe Borlot; Marissa Kellogg; Sean T Hwang; Anne Berg; Swaroop Aradhya Journal: Neurol Genet Date: 2021-12-16
Authors: Lata Vadlamudi; Carmen Maree Bennett; Melanie Tom; Ghusoon Abdulrasool; Kristian Brion; Ben Lundie; Hnin Aung; Chiyan Lau; Jonathan Rodgers; Kate Riney; Louisa Gordon Journal: J Clin Med Date: 2022-07-21 Impact factor: 4.964
Authors: Pia Zacher; Thomas Mayer; Frank Brandhoff; Tobias Bartolomaeus; Diana Le Duc; Martin Finzel; Anja Heinze; Susanne Horn; Chiara Klöckner; Gudrun Körber; Julia Hentschel; Malgorzata Kalita; Ilona Krey; Marina Nastainczyk-Wulf; Konrad Platzer; Johannes Rebstock; Bernt Popp; Mathias Stiller; Anne-Christin Teichmann; Rami Abou Jamra; Johannes R Lemke Journal: Genet Med Date: 2021-04-28 Impact factor: 8.822